Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Ana C. Garrido-Castro, Sara M. Tolaney, Lestat R. Ali et al.|Journal for ImmunoTherapy of Cancer|2025

Cited by 15